“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting
Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors
Clinical Scorecard: Plug-and-Play CAR T Platform Enables Post-Infusion Retargeting
At a Glance
Category Detail
Condition CAR T-cell therapy Key Mechanisms Modular CAR T-cell platform with meditope-enabled technology for post-infusion retargeting and expansion. Target Population Patients with heterogeneous tumors expressing different antigens. Care Setting Oncology and immunotherapy clinics.
Key Highlights
meCAR platform allows modification of CAR T-cell targeting post-infusion. Utilizes protein adaptors for enhanced T-cell expansion and redirection. Demonstrated comparable tumor-cell killing to conventional CAR T cells. Combination of adaptors with meCAR T cells reduced tumor burden and extended survival in mouse models. Dosing and pharmacokinetics of adaptors require careful optimization. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with tumors expressing multiple antigens.
Adaptors can enhance CAR T-cell functionality and flexibility in targeting.
Clinical Best Practices
Monitor adaptor concentrations to optimize CAR T-cell interactions. Consider the heterogeneity of tumor antigens when designing CAR T-cell therapies. Related Resources & Content
